T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.86B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.49B |
| 3 |
Broadcom
AVGO
|
+$1.29B |
| 4 |
Sempra
SRE
|
+$1.26B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PayPal
PYPL
|
+$1.66B |
| 2 |
HCA Healthcare
HCA
|
+$1.02B |
| 3 |
BNY
Bank of New York Mellon
BNY
|
+$949M |
| 4 |
American Tower
AMT
|
+$931M |
| 5 |
FRC
First Republic Bank
FRC
|
+$890M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.07% |
| 2 | Financials | 16.19% |
| 3 | Technology | 16.15% |
| 4 | Consumer Discretionary | 13.93% |
| 5 | Industrials | 9.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CZR
251
DELISTED
Caesars Entertainment Corporation
CZR
| $508M | 0.08% |
40,128,838
+40,076,681
| +76,839% | +$508M |
|
252
AstraZeneca
AZN
$246B
| $507M | 0.08% |
7,310,127
+185,219
| +3% | +$12.5M |
|
|
HDS
253
DELISTED
HD Supply Holdings, Inc.
HDS
| $505M | 0.08% |
12,616,378
+478,023
| +4% | +$17.6M |
|
254
Newmont
NEM
$124B
| $505M | 0.08% |
13,453,463
+176,115
| +1% | +$6.48M |
|
|
GRFS
255
Grifois
GRFS
$5.44B
| $505M | 0.08% |
22,016,635
+370,620
| +2% | +$8.23M |
|
256
Emerson Electric
EMR
$91.7B
| $494M | 0.08% |
7,095,460
-1,350,471
| -16% | -$87.5M |
|
257
Bright Horizons
BFAM
$3.76B
| $494M | 0.08% |
5,250,445
+1,667,026
| +47% | +$148M |
|
258
Archer Daniels Midland
ADM
$38.8B
| $493M | 0.08% |
12,308,809
-38,639
| -0.3% | -$1.59M |
|
259
Nucor
NUE
$61.9B
| $493M | 0.08% |
7,748,287
+579,165
| +8% | +$33.9M |
|
260
Simon Property Group
SPG
$71.2B
| $492M | 0.08% |
2,865,231
-58,262
| -2% | -$9.46M |
|
261
Canadian Pacific Kansas City
CP
$80.8B
| $488M | 0.08% |
13,348,095
-124,325
| -0.9% | -$4.33M |
|
|
KSU
262
DELISTED
Kansas City Southern
KSU
| $488M | 0.08% |
4,635,319
-8,225
| -0.2% | -$877K |
|
263
Las Vegas Sands
LVS
$29.6B
| $488M | 0.08% |
7,017,772
-863,619
| -11% | -$57.6M |
|
264
Neurocrine Biosciences
NBIX
$16.5B
| $483M | 0.08% |
6,231,030
-976,343
| -14% | -$66.6M |
|
|
FRC
265
DELISTED
First Republic Bank
FRC
| $481M | 0.08% |
5,546,274
-9,393,276
| -63% | -$890M |
|
266
MSCI
MSCI
$40.8B
| $476M | 0.08% |
3,762,680
-1,050,077
| -22% | -$131M |
|
267
Gartner
IT
$11.8B
| $473M | 0.08% |
3,842,953
+484,587
| +14% | +$58.8M |
|
268
Enovis
ENOV
$1.42B
| $471M | 0.08% |
6,904,343
+3,789,055
| +122% | +$255M |
|
269
Dentsply Sirona
XRAY
$2.31B
| $467M | 0.08% |
7,099,441
-5,255
| -0.1% | -$334K |
|
270
Amgen
AMGN
$224B
| $467M | 0.08% |
2,683,267
-110,647
| -4% | -$19.6M |
|
271
Atmos Energy
ATO
$28.6B
| $461M | 0.07% |
5,362,256
-37,551
| -0.7% | -$3.3M |
|
|
TMX
272
DELISTED
Terminix Global Holdings, Inc.
TMX
| $460M | 0.07% |
13,394,953
-951,924
| -7% | -$30.7M |
|
|
ATHN
273
DELISTED
Athenahealth, Inc.
ATHN
| $460M | 0.07% |
3,454,259
+458,393
| +15% | +$58.6M |
|
|
274
HCA Healthcare
HCA
$89.1B
| $458M | 0.07% |
5,211,569
-12,685,577
| -71% | -$1.02B |
|
275
Mattel
MAT
$4.29B
| $455M | 0.07% |
29,565,397
+1,347,092
| +5% | +$21.3M |
|
Similar funds
T. Rowe Price Associates's Q4 2017 Portfolio in Review
As of Q4 2017, T. Rowe Price Associates held 2,692 positions worth $616B, up 5.3% from $585B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
T. Rowe Price Associates's Q4 2017 filing shows 121 new, 947 increased, 1,282 reduced and 130 closed positions. Its largest new stake was CarGurus: 13,060,603 shares worth $374M. The largest sale was PayPal, an estimated $1.66B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 18% a quarter earlier, followed by Financials and Technology.
- T. Rowe Price Associates's largest Q4 2017 buy was CarGurus: 13,060,603 shares worth $374M.
- T. Rowe Price Associates added most to Tesla in Q4 2017, an estimated $1.86B increase.
- T. Rowe Price Associates's biggest Q4 2017 reduction was PayPal, cutting an estimated $1.66B.
- T. Rowe Price Associates fully exited Kite Pharma, Inc. in Q4 2017, selling an estimated $483M.
- T. Rowe Price Associates's ten largest holdings make up 19% of its $616B portfolio in Q4 2017.
- T. Rowe Price Associates opened 121 new positions and closed 130 in Q4 2017.
- T. Rowe Price Associates's portfolio value rose 5.3% quarter-over-quarter to $616B.
Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.